

Jenny Y Y Ooi

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/4693962/jenny-y-y-ooi-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

26
papers

1,497
citations

18
h-index

26
g-index

26
ext. papers

1,835
ext. citations

6.5
avg, IF

4.61
L-index

#	Paper	IF	Citations
26	Novel Lipid Species for Detecting and Predicting Atrial Fibrillation in Patients With Type 2 Diabetes. <i>Diabetes</i> , 2021 , 70, 255-261	0.9	4
25	Clusterin is regulated by IGF1-PI3K signaling in the heart: implications for biomarker and drug target discovery, and cardiotoxicity. <i>Archives of Toxicology</i> , 2020 , 94, 1763-1768	5.8	4
24	Translational Potential of Non-coding RNAs for Cardiovascular Disease. <i>Advances in Experimental Medicine and Biology</i> , 2020 , 1229, 343-354	3.6	3
23	Understanding Key Mechanisms of Exercise-Induced Cardiac Protection to Mitigate Disease: Current Knowledge and Emerging Concepts. <i>Physiological Reviews</i> , 2018 , 98, 419-475	47.9	56
22	Distinct lipidomic profiles in models of physiological and pathological cardiac remodeling, and potential therapeutic strategies. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2018 , 1863, 219-234	5	14
21	Lipidomic Profiles of the Heart and Circulation in Response to Exercise versus Cardiac Pathology: A Resource of Potential Biomarkers and Drug Targets. <i>Cell Reports</i> , 2018 , 24, 2757-2772	10.6	28
20	Identification of miR-34 regulatory networks in settings of disease and anti-miR-therapy: Implications for treating cardiac pathology and other diseases. <i>RNA Biology</i> , 2017 , 14, 500-513	4.8	38
19	The Interplay of Protein Coding and Non-Coding RNAs (circRNAs, lncRNAs) During Cardiac Differentiation. <i>EBioMedicine</i> , 2017 , 25, 9-10	8.8	5
18	The IGF1-PI3K-Akt Signaling Pathway in Mediating Exercise-Induced Cardiac Hypertrophy and Protection. <i>Advances in Experimental Medicine and Biology</i> , 2017 , 1000, 187-210	3.6	44
17	Inhibition of miR-154 Protects Against Cardiac Dysfunction and Fibrosis in a Mouse Model of Pressure Overload. <i>Scientific Reports</i> , 2016 , 6, 22442	4.9	36
16	Therapeutic potential of targeting microRNAs to regulate cardiac fibrosis: miR-433 a new fibrotic player. <i>Annals of Translational Medicine</i> , 2016 , 4, 548	3.2	4
15	Sex differences in response to miRNA-34a therapy in mouse models of cardiac disease: identification of sex-, disease- and treatment-regulated miRNAs. <i>Journal of Physiology</i> , 2016 , 594, 5959-5974	3.9	30
14	Pathophysiology of cardiac hypertrophy and heart failure: signaling pathways and novel therapeutic targets. <i>Archives of Toxicology</i> , 2015 , 89, 1401-38	5.8	337
13	HDAC inhibition attenuates cardiac hypertrophy by acetylation and deacetylation of target genes. <i>Epigenetics</i> , 2015 , 10, 418-30	5.7	83
12	miRNA therapeutics: a new class of drugs with potential therapeutic applications in the heart. <i>Future Medicinal Chemistry</i> , 2015 , 7, 1771-92	4.1	132
11	Dynamic changes in the cardiac methylome during postnatal development. <i>FASEB Journal</i> , 2015 , 29, 1329-43	0.9	47
10	Vascular histone deacetylation by pharmacological HDAC inhibition. <i>Genome Research</i> , 2014 , 24, 1271-84	4.7	64

9	MicroRNAs differentially regulated in cardiac and skeletal muscle in health and disease: potential drug targets?. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2014 , 41, 727-37	3	17
8	The therapeutic potential of miRNAs regulated in settings of physiological cardiac hypertrophy. <i>Future Medicinal Chemistry</i> , 2014 , 6, 205-22	4.1	49
7	Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling. <i>Blood</i> , 2014 , 124, 3829-30	2.2	235
6	Therapeutic silencing of miR-652 restores heart function and attenuates adverse remodeling in a setting of established pathological hypertrophy. <i>FASEB Journal</i> , 2014 , 28, 5097-110	0.9	61
5	The small-molecule BGP-15 protects against heart failure and atrial fibrillation in mice. <i>Nature Communications</i> , 2014 , 5, 5705	17.4	61
4	Silencing of miR-34a attenuates cardiac dysfunction in a setting of moderate, but not severe, hypertrophic cardiomyopathy. <i>PLoS ONE</i> , 2014 , 9, e90337	3.7	58
3	The yin and yang of adaptive and maladaptive processes in heart failure. <i>Drug Discovery Today: Therapeutic Strategies</i> , 2012 , 9, e163-e172		7
2	Investigation into the biological properties of the olive polyphenol, hydroxytyrosol: mechanistic insights by genome-wide mRNA-Seq analysis. <i>Genes and Nutrition</i> , 2012 , 7, 343-55	4.3	34
1	A brain-derived MeCP2 complex supports a role for MeCP2 in RNA processing. <i>Bioscience Reports</i> , 2011 , 31, 333-43	4.1	46